Sirolimus and Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis
In a study of patients with the rare multisystem disease lymphangioleiomyomatosis (LAM), responses to COVID-19 mRNA vaccines were similar with and without sirolimus treatment, letter